Merck to Present Phase 3 Data on Investigational Medicines Ertugliflozin and MK-1293 at the 76th Scientific Sessions of the American Diabetes Association

Dateline City: KENILWORTH, N.J. Additional Analyses from the TECOS Cardiovascular Safety Trial of JANUVIA® (sitagliptin) Also to Be Presented KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that researchers will present data from clinical trials of its investigational diabetes pipeline, JANUVIA® (sitagliptin), and new real-world research in more than 20 scientific data presentations at the 76th Scientific Sessions of the American Diabetes Association (ADA) being held in New Orleans, June 10-14, 2016. Language: English Contact: MerckMedia:Doris Li, 908-246-5701Kristen Drake, 908-236-4223orInvestors:Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Source: Merck.com - Corporate News - Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK ADA Source Type: news